TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM August 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain stat ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM May 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Cer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...

Neuronetics, Inc. (NASDAQ:STIM) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President and Chief Executive Officer Steve Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2022 Financial and Operating Results Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Neuronetics, Inc. (NASDAQ:STIM) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Partners Keith Sullivan - President and CEO Steve Furlong - CFO Conference Call Participants Adam Maeder - Piper Sandler Bill Plovanic - Canaccord Genuity Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics' Fourth Quarter 2021 Financial and Operating Results Conference Call. At this time, all participants are in a listen-o ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM March 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain state ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

COMPANY PRESENTATION NASDAQ: STIM November 2021 Disclaimers This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain statements in this presentation and the accompanying oral ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $13.8 million, an increase of 11% compared to $12.4 million in Q3 2020 [19] - US revenue increased by 10%, while international revenue rose by 24% [19] - Gross margin decreased to 77.2% from 78.7% in the prior year, primarily due to increased supply chain costs [20] - Net loss was $8.2 million or $0.31 per share, compared to a net loss of $3.4 million or $0.18 per share in 2020 [20] - EBITDA was negative $6.9 million, worsening from negative $2.2 million in 2020 [20] Business Line Data and Key Metrics Changes - US NeuroStar Advanced Therapy System revenue was $2.6 million, up 3% from the prior year [19] - US treatment session revenue increased by 13% to $10.3 million from $9.1 million in the previous year [19] - Revenue per active site was approximately $11,100, compared to $10,200 in the prior year [20] Market Data and Key Metrics Changes - The company sold 40 systems in the quarter, up from 39 in the prior year [19] - The expansion into new accounts was slower than expected due to a longer sales cycle [9][10] Company Strategy and Development Direction - The company is focusing on expanding relationships with national accounts and has recently signed exclusive agreements with Zion Healing and River Region Psychiatry [12][13] - The company aims to drive awareness and adoption of NeuroStar Advanced Therapy through marketing initiatives and partnerships [14][26] - The company is optimistic about future growth opportunities as the demand for non-drug alternatives for depression treatment rises [28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that revenue performance was below expectations but emphasized progress on strategic initiatives [18] - The company expects continued COVID-related challenges and seasonality to impact new patient starts during the holidays [22] - Management is encouraged by ongoing discussions with the FDA regarding potential label expansion [17][27] Other Important Information - The company incurred approximately $1.9 million in non-cash stock-based compensation expenses during the quarter [20] - Cash and cash equivalents as of September 30, 2021, were $99.4 million [21] Q&A Session Summary Question: How quickly can fundraising translate to new clinic openings and patient starts? - Management indicated that it typically takes about three months to get a clinic up and running [32] Question: What are the key metrics for Q4 guidance? - Management discussed the impact of a new financing program and anticipated seasonality effects on treatment sessions [36] Question: What revenue contribution can be expected from new partnerships? - Management noted that these partnerships could contribute significantly, with expectations of growth in revenue from national accounts [39] Question: What is the expected sales recovery for 2022? - Management expressed optimism about returning to 2019 levels for treatment session revenue and capital sales [44] Question: What is the nature of the new contracts signed? - The new contracts with Zion and River Region Psychiatry are based on a per-click model, moving away from fixed pricing [51] Question: What is the resistance to getting identified patients into treatment? - Management acknowledged the challenges in the patient onboarding process but expressed optimism about the effectiveness of their new screening tool [54]